CTI's last-minute discount fails to win NICE OK for Pixuvri
This article was originally published in Scrip
Executive Summary
A simple discount on the price of Cell Therapeutics' Pixuvri (pixantrone) has failed to convince NICE, the health technology appraisal institute for England and Wales, to recommend the drug for NHS funding. The last-minute patient access scheme has done nothing to reassure the institute about holes in the evidence supporting the drug.